de Jesus Mikhail, Chanda Anindita, Grabauskas Titas, Kumar Manish, Kim Agnes S
Department of Cardiology, University of Connecticut Hartford Hospital, Hartford, CT, United States.
Department of Internal Medicine, University of Connecticut School of Medicine, Farmington, CT, United States.
Front Oncol. 2024 Feb 12;14:1258991. doi: 10.3389/fonc.2024.1258991. eCollection 2024.
Lung cancer is the second most common cancer worldwide and the leading cause of cancer-related death. While survival rates have improved with advancements in cancer therapeutics, additional health challenges have surfaced. Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in patients with lung cancer. CVD and lung cancer share many risk factors, such as smoking, hypertension, diabetes, advanced age, and obesity. Optimal management of this patient population requires a full understanding of the potential cardiovascular (CV) complications of lung cancer treatment. This review outlines the common shared risk factors, the spectrum of cardiotoxicities associated with lung cancer therapeutics, and prevention and management of short- and long-term CVD in patients with non-small cell (NSCLC) and small cell (SCLC) lung cancer. Due to the medical complexity of these patients, multidisciplinary collaborative care among oncologists, cardiologists, primary care physicians, and other providers is essential.
肺癌是全球第二大常见癌症，也是癌症相关死亡的主要原因。尽管随着癌症治疗技术的进步，生存率有所提高，但其他健康挑战也随之出现。心血管疾病（CVD）是肺癌患者发病和死亡的主要原因。CVD和肺癌有许多共同的风险因素，如吸烟、高血压、糖尿病、高龄和肥胖。对这一患者群体进行最佳管理需要充分了解肺癌治疗潜在的心血管（CV）并发症。本综述概述了常见的共同风险因素、与肺癌治疗相关的心脏毒性范围，以及非小细胞（NSCLC）和小细胞（SCLC）肺癌患者短期和长期CVD的预防和管理。由于这些患者的病情复杂，肿瘤学家、心脏病学家、初级保健医生和其他医疗人员之间的多学科协作护理至关重要。
